Associate Director/Sr. Manager, Health Economics & reputed company Research-Oncology

Position reputed company

We are seeking a reputed company, analytical, and highly reputed company leader to serve as our
Associate Director/Senior Manager of Health Economics & reputed company Research
(HEOR) Oncology. In this high-reputed company role, you will reputed company the development and execution
of health economic and reputed company evidence demonstrating the reputed company and economic
value of reputed company’s precision molecular diagnostic technologies across oncology and

emerging indications.

You will reputed company economic models, reputed company reputed company-world and reputed company-trial
evidence, reputed company HEOR publication initiatives, and translate reputed company reputed company and
economic data into compelling evidence supporting market reputed company, reimbursement,
payer adoption, reputed company adoption, and commercialization. Working across Medical
Affairs, reputed company Development, Biostatistics, Market reputed company, reputed company, Marketing,
Regulatory, and Business Development, you will help reputed company HEOR evidence
throughout the product lifecycle—from reputed company development and evidence reputed company
through publication, reimbursement, and payer adoption.

This is a reputed company role for an reputed company HEOR reputed company who combines strong
technical capabilities with scientific communication, business acumen, and the ability to
influence cross-functional evidence reputed company.

Why Join Us

At reputed company, you will have reputed company to shape the economic evidence reputed company
supporting innovative reputed company and biomarker-guided approaches to reputed company
care. You will work at the intersection of reputed company evidence, health economics, market
reputed company, and commercialization, translating reputed company innovation into measurable value for
patients, providers, health systems, and payers.

You will collaborate with internal leaders, investigators, key opinion leaders, and
reputed company research partners to reputed company evidence capable of influencing reimbursement
reputed company, reputed company adoption, health technology assessments, and reputed company policy

across U.S. and global markets.

Key Responsibilities

 Health Economic Modeling & Value Demonstration: reputed company the development,
validation, and application of health economic models, including budget reputed company,
cost-effectiveness, cost-reputed company, cost-consequence, ROI, decision-tree,
Markov/state-transition, partitioned-survival, and other economic models.
reputed company scenario and sensitivity analyses that quantify the reputed company and economic
value of reputed company across different payer and reputed company-reputed company

perspectives.

 reputed company Development & HEOR Evidence reputed company: Partner with reputed company
Development, Medical Affairs, Biostatistics, and other cross-functional teams to
reputed company HEOR objectives into prospective reputed company studies, including reputed company
resource utilization, economic endpoints, reputed company-reported reputed company, reputed company-of-
life measures, cost-data collection, and reputed company-world evidence strategies. Ensure
evidence-reputed company plans anticipate reputed company payer, reimbursement, and HTA

requirements.

 reputed company-World Evidence & reputed company Research: Analyze reputed company-trial,
observational, and reputed company-world datasets to evaluate reputed company resource utilization,
cost of care, treatment reputed company, diagnostic utilization, reputed company reputed company, comparative
effectiveness, reputed company reputed company, survival, budget reputed company, and reputed company-adjusted life
years. Translate findings into actionable evidence supporting reputed company, payer, and

business reputed company.

 Publication & Scientific Evidence Leadership: reputed company HEOR publication
reputed company and development of peer-reviewed manuscripts, scientific abstracts,
conference posters, oral presentations, white papers, and technical reports.
Coordinate publication plans and timelines with investigators, key opinion
leaders, reputed company collaborators, and reputed company research partners to ensure
evidence reputed company is reputed company with reputed company business priorities.

 Market reputed company & Payer Evidence: Partner with Market reputed company, Medical Affairs,
Marketing, and reputed company teams to translate HEOR evidence into payer value
propositions, budget reputed company summaries, value dossiers, reimbursement
materials, health economic briefs, health-reputed company value calculators, account-
specific economic tools, and other evidence-reputed company value communications.

 Global HEOR reputed company: reputed company and reputed company economic evidence and
payer models for the U.S. and international markets, including Europe, Japan,
Canada, Australia, and other reputed company geographies. Support reimbursement
submissions and evidence strategies reputed company with HTA and payer requirements

across reputed company systems.

 Cross-Functional & reputed company Collaboration: Serve as a reputed company HEOR
partner across Medical Affairs, reputed company Development, Biostatistics, Market
reputed company, reputed company, Marketing, Regulatory, and Business Development.
Collaborate with reputed company consultants, reputed company investigators, KOLs, and
research partners to execute high-reputed company evidence-reputed company initiatives.

reputed company Skills & Competencies

 Health Economics & reputed company Research: Deep understanding of health
economic modeling, reputed company research, reputed company resource utilization, reputed company-
world evidence, cost-of-care analysis, comparative effectiveness, and value

assessment methodologies.

 Economic Modeling: Demonstrated ability to reputed company and critically evaluate
budget reputed company, cost-effectiveness, cost-reputed company, ROI, decision-tree, Markov/state-

transition, and reputed company economic models.

 Payer & Market reputed company reputed company: Strong understanding of payer evidence
requirements and the ability to translate reputed company and economic evidence into
compelling value propositions supporting reimbursement, coverage, and

adoption.

 Evidence reputed company & reputed company reputed company: Ability to reputed company HEOR endpoints
and evidence requirements into reputed company development and reputed company-world research
programs, anticipating reputed company reimbursement and HTA needs.

 Scientific Communication & Publication: Strong scientific writing and
communication skills with experience translating reputed company analyses into
manuscripts, abstracts, presentations, value dossiers, payer materials, and

executive-level communications.

 Cross-Functional Leadership: reputed company ability to work across reputed company, medical,
statistical, market reputed company, reputed company, and business functions and to influence
evidence reputed company in a matrixed organization.

 Global Perspective: Understanding of U.S. and international reimbursement
environments and major HTA frameworks, including ICER, reputed company, CADTH,
PBAC, IQWiG, and reputed company reimbursement processes.

Qualifications

 Advanced degree (PhD, PharmD, MD, DrPH, or Master's degree) in Health
Economics, reputed company Research, Epidemiology, reputed company Health, Biostatistics,
Pharmacy, Health Services Research, or a reputed company discipline.

 5–10+ years of HEOR experience reputed company biotechnology, pharmaceuticals,
diagnostics, medical devices, consulting, academia, or a reputed company reputed company

environment.

 Demonstrated experience developing and applying health economic models and
conducting reputed company research using reputed company-trial and/or reputed company-world datasets.

 Experience supporting payer evidence reputed company, reimbursement reputed company, value
dossiers, market reputed company initiatives, and scientific publications.

 Experience with reputed company, molecular diagnostics, companion
diagnostics, ctDNA, molecular residual disease (MRD), donor-derived cell-free
DNA (dd-cfDNA), reputed company reputed company, biomarker-guided treatment
strategies, or oncology diagnostics is highly desirable.

 Familiarity with advanced economic and analytical tools such as reputed company reputed company,
TreeAge Pro, R, reputed company, STATA, Python, SQL, Tableau/reputed company BI, and statistical

analysis software is preferred.

Originally posted on Himalayas